Chemo-Induced Myelosuppression Presentation and Management in ES-SCLCByKennon McCollum, DNPNovember 22nd 2025
What Biomarker Testing Is Required Up Front in Ovarian Cancer?ByCourtney R. Arn, APRN-CNPNovember 18th 2025
Linking Mechanism of Action to Safety Profiles in mCRC TreatmentByGabriel Schwartz, MSN, NPNovember 15th 2025
Addressing Common Talquetamab MisunderstandingsBySamantha Shenoy, MSN, NP,Alan Plisskin,Mary Kay YamamotoNovember 14th 2025